Dialysis for Chronic Kidney Failure
JAMA · 12.11.2024 · 332 (18) · 1559
DOI: 10.1001/jama.2024.16338 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JAMA, erschienen am 12.11.2024. Verfasst von Jennifer E Flythe und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, UNC School of Medicine, Chapel Hill. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Peritoneal Dialysis, Renal Dialysis. Die Arbeit wurde bisher 209-mal zitiert (Crossref) und nennt 110 Literaturangaben.
Abstract (Originalsprache)
Importance More than 3.5 million people worldwide and 540 000 individuals in the US receive maintenance hemodialysis or peritoneal dialysis for the treatment of chronic kidney failure. The 5-year survival rate is approximately 40% after initiation of maintenance dialysis. Observations Hemodialysis and peritoneal dialysis remove metabolic waste and excess body water and rebalance electrolytes to sustain life. There is no recommended estimated glomerular filtration rate (eGFR) threshold for initiating dialysis, and patient-clinician shared decision-making should help determine when to initiate dialysis. Persistent signs and symptoms of uremia (eg, nausea, fatigue) and volume overload (eg, dyspnea, peripheral edema), worsening eGFR, metabolic acidosis, and hyperkalemia inform the timing of therapy initiation. A randomized clinical trial reported no mortality benefit to starting dialysis at higher eGFR (10-14 mL/min/1.73 m 2 ) vs lower eGFR (5-7 mL/min/1.73 m 2 ) levels. Observational data suggested no differences in 5-year mortality with use of hemodialysis vs peritoneal dialysis. Cardiovascular (eg, arrhythmias, cardiac arrest) and infection-related complications of maintenance dialysis are common. In the US, hemodialysis catheter–related bloodstream infections occur at a rate of 1.1 to 5.5 episodes per 1000 catheter-days and affect approximately 50% of patients within 6 months of catheter placement. Peritonitis occurs at a rate of 0.26 episodes per patient-year and affects about 30% of individuals in the first year of peritoneal dialysis therapy. Chronic kidney failure–related systemic complications, such as anemia, hyperphosphatemia, hypocalcemia, and hypertension, often require pharmacologic treatment. Hypotension during dialysis, refractory symptoms (eg, muscle cramps, itching), and malfunction of dialysis access can interfere with delivery of dialysis. Conclusions and Relevance In 2021, more than 540 000 patients in the US received maintenance hemodialysis or peritoneal dialysis for treatment of chronic kidney failure. Five-year survival rate after initiation of maintenance dialysis is approximately 40%, and the mortality rate is similar with hemodialysis and peritoneal dialysis. Decisions about dialysis initiation timing and modality are influenced by patient symptoms, laboratory trajectories, patient preferences, and therapy cost and availability and should include shared decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- University of North Carolina Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, UNC School of Medicine, Chapel Hill.
- Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill.
- Division of Nephrology, University of Washington School of Medicine, Seattle.
- Section of Nephrology, Seattle VA Medical Center, Seattle, Washington.
Zitieren
APA
Flythe, J. E., & Watnick, S. (2024). Dialysis for Chronic Kidney Failure. JAMA, 332(18), 1559. https://doi.org/10.1001/jama.2024.16338
Vancouver
Flythe JE, Watnick S. Dialysis for Chronic Kidney Failure. JAMA. 2024;332(18):1559. doi:10.1001/jama.2024.16338
BibTeX
@article{Flythe2024,
author = {Flythe, Jennifer E and Watnick, Suzanne},
title = {Dialysis for Chronic Kidney Failure},
journal = {JAMA},
year = {2024},
volume = {332},
number = {18},
pages = {1559},
doi = {10.1001/jama.2024.16338}
}
EUVIMED